Cancer Genetics (NASDAQ:CGIX – Get Free Report) is one of 44 publicly-traded companies in the “Medical Laboratories” industry, but how does it contrast to its competitors? We will compare Cancer Genetics to similar businesses based on the strength of its profitability, analyst recommendations, valuation, earnings, risk, institutional ownership and dividends.
Analyst Recommendations
This is a summary of recent ratings and target prices for Cancer Genetics and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cancer Genetics | 0 | 0 | 0 | 0 | N/A |
| Cancer Genetics Competitors | 207 | 1073 | 1827 | 32 | 2.54 |
As a group, “Medical Laboratories” companies have a potential upside of 33.81%. Given Cancer Genetics’ competitors higher probable upside, analysts clearly believe Cancer Genetics has less favorable growth aspects than its competitors.
Volatility and Risk
Institutional and Insider Ownership
8.9% of Cancer Genetics shares are held by institutional investors. Comparatively, 50.9% of shares of all “Medical Laboratories” companies are held by institutional investors. 15.0% of Cancer Genetics shares are held by company insiders. Comparatively, 22.2% of shares of all “Medical Laboratories” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Cancer Genetics and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cancer Genetics | N/A | N/A | N/A |
| Cancer Genetics Competitors | -1,581.30% | -77.10% | -32.60% |
Valuation and Earnings
This table compares Cancer Genetics and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Cancer Genetics | $6.33 million | N/A | -0.08 |
| Cancer Genetics Competitors | $1.14 billion | -$20.89 million | -3.07 |
Cancer Genetics’ competitors have higher revenue, but lower earnings than Cancer Genetics. Cancer Genetics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Summary
Cancer Genetics beats its competitors on 5 of the 9 factors compared.
About Cancer Genetics
Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson’s Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
